MAPK/ERK SIGNALING IN GLIOMAS MODULATES INTERFERON RESPONSES, PROMOTES TUMOR-MICROGLIA CROSSTALK, AND CONFERS SUSCEPTIBILITY TO ANTI-PD-1 AND ANTI-CTLA-4 IMMUNOTHERAPY

被引：0
|
作者：
Kim, Kwang-Soo [1 ]
Zhang, Junyi [2 ]
Dmello, Crismita [1 ]
Grabis, Elena [2 ]
Arrieta, Victor [1 ]
Habashy, Karl [1 ]
Zhao, Junfei [3 ]
Duffy, Joseph [1 ]
Gould, Andrew [1 ]
Chen, Li [1 ]
Balyasnikova, Irina [1 ]
Canoll, Peter [3 ]
Sims, Peter [3 ]
Rabadan, Raul [3 ]
Lee-Chang, Catalina [1 ]
Heiland, Dieter Henrik [2 ]
Sonabend, Adam [1 ]
机构：
[1] Northwestern Univ, Chicago, IL USA
[2] Univ Freiburg, Freiburg, Germany
[3] Columbia Univ, New York, NY USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NOAE165.02
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse.
    Mok, Stephen
    Duffy, Colm R.
    Anang, Nana-Ama A.
    Allison, James P.
    CANCER RESEARCH, 2020, 80 (19) : 42 - 42
  • [22] Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
    Xiang, Ze
    Li, Jiayuan
    Zhang, Zhengyu
    Cen, Chao
    Chen, Wei
    Jiang, Bin
    Meng, Yiling
    Wang, Ying
    Berglund, Bjoern
    Zhai, Guanghua
    Wu, Jian
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Gauci, Marie-Lea
    Boudou, Philippe
    Baroudjian, Barouyr
    Vidal-Trecan, Tiphaine
    Da Meda, Laetitia
    Madelaine-Chambrin, Isabelle
    Basset-Seguin, Nicole
    Bagot, Martine
    Pages, Cecile
    Mourah, Samia
    Resche-Rigon, Matthieu
    Pinel, Sylvine
    Sassier, Marion
    Rouby, Franck
    Eftekhari, Pirayeh
    Lebbe, Celeste
    Gautier, Jean-Francois
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1197 - 1208
  • [24] Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
    Sove, Richard J.
    Verma, Babita K.
    Wang, Hanwen
    Ho, Won Jin
    Yarchoan, Mark
    Popel, Aleksander S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)
  • [25] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
    Marie-Léa Gauci
    Philippe Boudou
    Barouyr Baroudjian
    Tiphaine Vidal-Trecan
    Laetitia Da Meda
    Isabelle Madelaine-Chambrin
    Nicole Basset-Seguin
    Martine Bagot
    Cécile Pages
    Samia Mourah
    Matthieu Resche-Rigon
    Sylvine Pinel
    Marion Sassier
    Franck Rouby
    Pirayeh Eftekhari
    Céleste Lebbé
    Jean-François Gautier
    Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
  • [26] TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy
    Liu, Heng-Jia
    Lizotte, Patrick H.
    Du, Heng
    Speranza, Maria C.
    Lam, Hilaire C.
    Vaughan, Spencer
    Alesi, Nicola
    Wong, Kwok-Kin
    Freeman, Gordon J.
    Sharpe, Arlene H.
    Henske, Elizabeth P.
    JCI INSIGHT, 2018, 3 (08):
  • [27] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas
    Kim, Kwang-Soo
    Habashy, Karl
    Gould, Andrew
    Zhao, Junfei
    Najem, Hinda
    Amidei, Christina
    Saganty, Ruth
    Arrieta, Victor A.
    Dmello, Crismita
    Chen, Li
    Zhang, Daniel Y.
    Castro, Brandyn
    Billingham, Leah
    Levey, Daniel
    Huber, Olivia
    Marques, Marilyn
    Savitsky, David A.
    Morin, Benjamin M.
    Muzzio, Miguel
    Canney, Michael
    Horbinski, Craig
    Zhang, Peng
    Miska, Jason
    Padney, Surya
    Zhang, Bin
    Rabadan, Raul
    Phillips, Joanna J.
    Butowski, Nicholas
    Heimberger, Amy B.
    Hu, Jian
    Stupp, Roger
    Chand, Dhan
    Lee-Chang, Catalina
    Sonabend, Adam M.
    NEURO-ONCOLOGY, 2024, 26 (11) : 2044 - 2060
  • [28] Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
    Hulen, Thomas Morgan
    Friese, Christina
    Kristensen, Nikolaj Pagh
    Granhoj, Joachim Stoltenborg
    Borch, Troels Holz
    Peeters, Marlies J. W.
    Donia, Marco
    Andersen, Mads Hald
    Hadrup, Sine Reker
    Svane, Inge Marie
    Met, Ozcan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
    Huang, Yi
    Chen, Zhijian
    Shen, Gang
    Fang, Shuogui
    Zheng, Junjiong
    Chi, Zepai
    Zhang, Yuanfeng
    Zou, Yitong
    Gan, Qinghua
    Liao, Chengxiao
    Yao, Yuhui
    Kong, Jianqiu
    Fan, Xinxiang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [30] Patients with advanced melanoma who benefit from the addition of anti-CTLA-4 to anti-PD-1 have a distinct tumor microenvironment (TME)
    D'Amiano, N. M.
    Will, E.
    Deutsch, J. S.
    Engle, L.
    Berry, S.
    Green, B.
    Szalay, A.
    Lipson, E.
    Taube, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S101 - S101
12345